JPMorgan Chase & Co. Raises Insmed (NASDAQ:INSM) Price Target to $72.00

Insmed (NASDAQ:INSM – Free Report) had its target price lifted by JPMorgan Chase & Co. from $55.00 to $72.00 in a report issued on Thursday morning, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. INSM has been the topic of a number of other research reports. Wells Fargo & Company […]

Leave a Reply

Your email address will not be published.

Previous post Benchmark Increases Plexus (NASDAQ:PLXS) Price Target to $120.00
Next post Genmab A/S (NASDAQ:GMAB) Earns “Buy” Rating from HC Wainwright